While cladribine does appear to be very effective in treating MS, people with MS who receiving cladribine appear more likely to develop serious infections and cancers. Data suggests that cladribine reduces or eliminates many of the cell types (such as T cells and B cells) involved in MS. Cladribine has cytotoxic (cell-killing) properties and works by depleting lymphocytes. It is however being studied as an oral cell-killing agent in MS. This product is currently approved as an injectable agent for Hairy Cell Leukemia. The following are some of the oral therapies that in the future may expand the menu of treatment options for MS. We'll need that same partnership to help decide who is most appropriate for a switch to one of the new oral medications,” he says. “One thing I love about working with the MS community is the sense of partnership that we have in making decisions. Will your insurance cover the new medication right away or will it take a while for the drug to get on your formulary? If it's on your formulary, what will the co-pay be? These include what information is known and not known about the safety and effectiveness of the new drug. Many factors will go into that decision, according to Dr. If you are stable on your current injectable medication and are having no side effects, it's fair to ask whether a switch to a new oral drug is worth it.”
#Dimethyl fumarate copay assistance teva how to#
“As these oral medications become available we will need to think about how to use them safely and effectively. We appear to be very close to having more convenient therapies in the form of oral medications,” says MSF Medical Advisor, Ben Thrower, M.D. Future therapeutic goals would include more therapies for progressive forms of MS, therapies to repair damage in the central nervous system, and more effective and convenient therapies.
“We've come a long way in our ability to potentially slow the course of MS for many people. They are discouraged from switching based solely on route of administration.
People with MS are encouraged to discuss the pros and cons of the oral agents with their physicians.
The decision to change to an orally administered product is going to be a complicated one. However, just because a product is administered orally does not make it better or safer than existing therapies. Within the next several years, many if not all of these products are expected to be approved to treat MS. Today, there is a lot of excitement in the MS community because several oral products have shown promising results in clinical trials. With the release of this product, the transformation in the treatment of MS began. The first disease-modifying drug, Betaseron®, became commercially available in 1993. The treatment options for multiple sclerosis have changed dramatically during the last 16 years.
0 kommentar(er)
